Market Overview

Cerus Announces Deal with Swiss Red Cross for Initial Deployment of INTERCEPT Blood System

Related CERS
Cerus Reports US Phase 2 Clinical Trial of INTERCEPT Red Blood Cells Met Primary Endpoint
Benzinga's Top #PreMarket Gainers

Cerus Corporation (NASDAQ: CERS) announced today that it has signed a two-year purchase agreement with two regional Swiss Red Cross Blood Services for deployment of the INTERCEPT Blood System for plasma in Lausanne and Zurich. These two pilot centers supply an estimated 15,000 plasma units annually.

Posted-In: News

 

Related Articles (CERS)

Around the Web, We're Loving...

Get Benzinga's Newsletters